A147 RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB– AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN’S STUDIES

Ustekinumab(UST) has been shown to induce & maintain clinical response & remission in moderate-severe Crohn’s disease(CD) in 2 induction[(UNITI-1(anti-TNF failures) & UNITI-2(anti-TNF non-failures) & 1 maintenance(IM-UNITI)] randomized, PBO-controlled Ph3 trials. We evaluated efficacy (response & remission) for all pts who received an IV induction dose of approximately 6mg/kg, including responders(CDAI decrease ≥100) & non-responders, 8wks after...